Search results for "Azetidine"

showing 3 items of 33 documents

The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes ?

2009

Ezetimibe represents the first of a new class of agents, the cholesterol absorption inhibitors, able to reduce low-density lipoproteins (LDL)-cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. To-date all the data regarding the efficacy of ezetimibe comes from the studies of its lipid-lowering power. Yet, recent findings from the ENHANCE study on atherosclerosis progression showed that the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolemia did not affect the mean change in carotid intima-media thickness, although a significant reduction in LDL-cholesterol levels was present. Therefore, we cannot exclude that e…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthFamilial hypercholesterolemiaBioinformatics2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundEzetimibePredictive Value of TestsInternal medicinemedicineAnimalsHumansProspective cohort studyCardiovascular risk Cholesterol LDL size Small dense LDLDyslipidemiasEzetimibe LDL-cholesterolCholesterolVascular diseasebusiness.industryAnticholesteremic AgentsHypertriglyceridemiaReproducibility of ResultsCholesterol LDLEzetimibemedicine.diseaseTreatment OutcomeEndocrinologychemistrySimvastatinAzetidinesDrug Therapy Combinationlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersDyslipidemiamedicine.drug
researchProduct

Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents

2014

Abstract Adipose tissue is an endocrine organ that secretes a number of hormones and metabolically active substances that impact energy metabolism and insulin sensitivity. These inflammatory markers are collectively referred to as adipocytokines, or adipokines. Adipose tissue's functional capacity and metabolic activity vary among individuals, thus partly explaining the incomplete overlap between obesity and the metabolic syndrome. The functional failure of adipose tissues results in changed energy delivery and impaired glucose consumption, triggering self-regulatory mechanisms to maintain homeostasis. Antihyperglycemic, hypolipidemic, antiobesity, and angiotensin II receptor blocker drugs …

medicine.medical_specialtyLipoproteinsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineAdipose tissueIncretinsNiacinAnti-Obesity AgentsInsulin resistanceAdipokinesInternal medicineInternal MedicineAnimalsHumansHypoglycemic AgentsInsulinMedicineHypolipidemic AgentsMetabolic Syndromebusiness.industryInsulinFibric AcidsEzetimibemedicine.diseaseLipidsMetforminGlucoseEndocrinologyAdipose TissueHypolipidemic AgentsAzetidinesThiazolidinedionesAnti-Obesity AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceMetabolic syndromebusinessHormoneMetabolic Syndrome and Related Disorders
researchProduct

The effect of ezetimibe on NAFLD

2015

NAFLD has become the most common liver disorder in countries, where obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are common. The strong association between these conditions and the risk of cardiovascular disease make treatment crucial. Possible interventions for NAFLD target excess body weight, insulin resistance, inflammation, oxidative stress or intestinal lipid absorption. Administration of combination therapy with a statin plus ezetimibe, associated with lifestyle changes, may represent an effective strategy because of the strong reduction in low-density lipoprotein cholesterol levels. Combination therapy is often more effective, especially when complementary …

medicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classBioinformaticsLiver disorderInsulin resistanceEzetimibeInternal medicineInternal MedicineAnimalsHumansMedicinebusiness.industryAnticholesteremic AgentsIntestinal lipid absorptionnutritional and metabolic diseasesGeneral MedicineLipid Metabolismmedicine.diseaseEzetimibeTreatment OutcomeEndocrinologyCholesterolLiverAzetidinesDrug Therapy CombinationMetabolic syndromebusinessCardiology and Cardiovascular MedicineNon-alcoholic steatohepatitiDyslipidemiamedicine.drugNon-alcoholic fatty liver disease
researchProduct